Caremo Pharmaceutical Honored as "2022 Best Emerging Preclinical CRO/CDMO Enterprise"!

The virtual release ceremony of the "2022 China Biopharma Innovation Ecosystem Leadership Awards" recently concluded, where Caremo Pharmaceutical was recognized as the "2022 Best Emerging Preclinical CRO/CDMO Enterprise" (Contract Research Organization/Contract Development and Manufacturing Organization).

As a strategic high ground in global technological and economic competition, the biopharmaceutical industry thrives on innovation. Guided by the China Pharmaceutical News Information Association, the authoritative evaluation committee—comprising the editorial board of Pharmaceutical Progress journal, China Biopharma Innovation & Translation Alliance, and Yaokahui Think Tank—partnered with Pharmadl Database and Industrial Securities to establish this third annual "China Biopharma Innovation Ecosystem Leadership Awards". Through multidimensional analysis of authoritative data and expert validation, the rigorous assessment process evaluated enterprises across five critical dimensions:

——Leadership (Innovation Impact)

——Scale (Industrial Capacity)

——Stability (Operational Excellence)

——Growth (Development Momentum)

——Strategy (Future Roadmap)

This accolade affirms Caremo's technological prowess, professional expertise, innovation capabilities, and growth trajectory. Moving forward, we remain committed to collaborating with global biotech and pharmaceutical partners across the entire R&D value chain—from target validation through commercialization. By addressing differentiated client needs through flexible collaboration models, Caremo will continue advancing its integrated, end-to-end drug discovery and production platform, delivering comprehensive technical and industrial support.

On the long pharmaceutical R&D Road,

Caremo stays true to its founding principles and mission,

Born for health and empowered for innovation!